How Cancer Cells Escape Death and Spread to the Liver — New Targets Revealed
A new review uncovers how colorectal cancer cells resist programmed death and hijack immune processes to colonize the liver, pointing to novel therapies.
Summary
Colorectal cancer (CRC) kills primarily through metastasis, with the liver being the most common site. This review examines two cell death processes — anoikis, triggered when cancer cells detach from their matrix, and NETosis, a neutrophil death mode releasing DNA traps — and how their interplay drives liver metastasis. CRC cells develop anoikis resistance to survive in circulation, while neutrophil extracellular traps (NETs) remodel tissue, suppress immunity, and promote tumor seeding. Using bioinformatics analysis, the authors identify shared signaling pathways including PI3K/AKT, MAPK, and EMT, along with biomarkers like MUC13, GLI2, SIRT6, and FASN. Therapeutic strategies targeting integrins, EGFR, NET components, and autophagy inhibitors are proposed as promising intervention points.
Detailed Summary
Colorectal cancer is among the deadliest cancers worldwide, and the majority of fatalities stem from metastatic disease — particularly spread to the liver. Understanding the molecular mechanisms that enable this spread is critical for developing effective treatments. This review focuses on two underexplored but interconnected cell death pathways that paradoxically fuel metastasis when dysregulated.
Anoikis is a form of programmed cell death normally triggered when cells detach from the extracellular matrix (ECM). In healthy tissue, this prevents displaced cells from surviving in foreign environments. However, CRC cells frequently develop anoikis resistance, allowing them to survive in the bloodstream and seed distant organs. NETosis, meanwhile, is a specialized neutrophil death process that releases web-like structures of DNA and proteins called neutrophil extracellular traps (NETs). While NETs serve immune functions, in cancer contexts they promote tumor progression by remodeling the ECM, enabling immune evasion, and stimulating angiogenesis.
The authors conducted a bioinformatics-informed review to map the crosstalk between anoikis and NETosis in colorectal cancer liver metastasis (CRCLM). They identified shared signaling hubs — notably PI3K/AKT, MAPK, and epithelial-mesenchymal transition (EMT) pathways — that both processes exploit. Key biomarkers at the intersection include MUC13, GLI2, SIRT6, and FASN, which may serve as diagnostic or therapeutic targets.
Therapeutic strategies discussed include integrin and EGFR inhibitors to restore anoikis sensitivity, DNase I and CXCR2 antagonists to disrupt NETs, and autophagy inhibitors such as chloroquine, hydroxychloroquine, and azithromycin to block survival mechanisms.
As a review relying on existing literature and bioinformatics rather than original experimental data, findings require prospective validation. Nevertheless, the framework offers a compelling roadmap for combination therapies targeting metastatic CRC.
Key Findings
- CRC cells develop anoikis resistance enabling survival in circulation and liver colonization.
- NETs promote liver metastasis via immune evasion, ECM remodeling, and angiogenesis.
- PI3K/AKT, MAPK, and EMT pathways are shared mechanistic links between anoikis and NETosis.
- Biomarkers MUC13, GLI2, SIRT6, and FASN identified at the anoikis–NETosis intersection.
- Integrin inhibitors, EGFR blockers, DNase I, and autophagy inhibitors proposed as therapeutic strategies.
Methodology
This is a narrative and bioinformatics-informed review, not an original experimental study. The authors synthesized published literature on anoikis and NETosis mechanisms and used bioinformatics analysis to identify shared pathways and biomarkers relevant to colorectal cancer liver metastasis.
Study Limitations
The study is a review without original experimental or clinical data, limiting causal conclusions. Bioinformatics-derived pathway connections require wet-lab and clinical validation before therapeutic application. The interplay between anoikis and NETosis in human CRCLM patients remains to be directly demonstrated.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.